Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9750690 | 0.71 | MAPT (0.31) | — | |
| SCHEMBL8371624 | 0.71 | S100A4 (0.48) | — | |
| Ligustrazine SCHEMBL77624 | 0.66 | LMNA (0.41) | KDM4EALDH1A1LMNA | |
| Ligustrazine SCHEMBL27509607 | 0.66 | LMNA (0.41) | KDM4EALDH1A1LMNA | |
| Ligustrazine SCHEMBL6069024 | 0.64 | CA5A (0.43) | EGFRPTK2PTGS1PTGS2KDM4E | |
| Ligustrazine SCHEMBL583011 | 0.62 | KDM4E (0.39) | KDM4EALDH1A1LMNA | |
| Ligustrazine SCHEMBL583535 | 0.62 | KDM4E (0.39) | KDM4EALDH1A1LMNA | |
| SCHEMBL13926212 | 0.62 | — | — | |
| SCHEMBL12667564 | 0.62 | — | — | |
| SCHEMBL12340091 | 0.59 | KDM4E (0.37) | KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230197361-A1 | CONDUCTIVE TWO-DIMENSIONAL (2D) COVALENT ORGANIC FRAMEWORKS (COFS) AND METHOD OF MAKING AN ELECTRODE MATERIAL | UNIV KING ABDULLAH SCI & TECH (SA) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230197361-A1 | CONDUCTIVE TWO-DIMENSIONAL (2D) COVALENT ORGANIC FRAMEWORKS (COFS) AND METHOD OF MAKING AN ELECTRODE MATERIAL | TET3, TET1, ALKBH2 | EGFR 2289/4885PTK2 771/4885PTGS1 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.